Expertise in
1
conditions

Yu-jen Fang

Yun Lin Branch, 
Douliu, TNQ, TW 
Expertise in
1
conditions
Yun Lin Branch, 
Douliu, TNQ, TW 
OverviewLocationsClinical Research

Overview

Yu-jen Fang practices in Douliu, Taiwan. Fang is highly rated in 1 condition, according to our data. Their top areas of expertise are Helicobacter Pylori Infection, Hepatitis, Hepatitis C, Indigestion, and Endoscopy.

Their clinical research consists of co-authoring 45 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Yun Lin Branch, Douliu, TNQ, Taiwan
Other Locations
Hsin Chu Branch, Yun Lin Branch, Taipei, TNQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

The Efficacy and Safety of TAF as a Prophylactic Antiviral Agent for HBsAg-positive Cancer Patients Receiving Chemotherapy
The Efficacy and Safety of TAF as a Prophylactic Antiviral Agent for HBsAg-positive Cancer Patients Receiving Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2024
Intervention Type: Drug
Study Drug: Tenofovir Alafenamide
Study Phase: Phase 4
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for Treatment-Naive and Treatment-Experienced Non-Cirrhotic Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for Treatment-Naive and Treatment-Experienced Non-Cirrhotic Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis
Enrollment Status: Completed
Publish Date: July 19, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 1 Less Clinical Trial

45 Total Publications

Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease.
Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease.
Journal: Gut
Published: October 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Fang's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile